ExodusPoint Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

ExodusPoint Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.18M	Sell	85,530 -161,258	-65%	-$9.34M	0.06%	326
2025 Q4	$10.2M	Buy	+246,788	New	+$9.57M	0.08%	256
2025 Q3	–	Sell	-75,079	Closed	-$1.4M	–	1654
2025 Q2	$1.4M	Buy	+75,079	New	+$1.41M	0.01%	861
2024 Q2	–	Sell	-16,996	Closed	-$510K	–	1623
2024 Q1	$510K	Buy	+16,996	New	+$369K	﹤0.01%	1133
2021 Q2	–	Sell	-1,210	Closed	-$229K	–	2454
2021 Q1	$229K	Buy	+1,210	New	+$204K	﹤0.01%	1821
2020 Q3	–	Sell	-2,736	Closed	-$329K	–	1848
2020 Q2	$329K	Buy	+2,736	New	+$385K	0.01%	1277

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ExodusPoint Capital Management's DNTH Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 65% in Q1 2026, selling an estimated $9.34M and leaving 85,530 shares worth $7.18M. The position accounts for 0.06% of the portfolio, ranked #326.

ExodusPoint Capital Management first reported a position in DNTH in Q2 2020 and has held it in 6 quarters since. The position peaked at $10.2M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

ExodusPoint Capital Management held 85,530 shares of Dianthus Therapeutics worth $7.18M as of Q1 2026.
ExodusPoint Capital Management sold 161,258 Dianthus Therapeutics shares in Q1 2026, an estimated $9.34M.
Dianthus Therapeutics made up 0.06% of ExodusPoint Capital Management's portfolio in Q1 2026, its #326 holding.
ExodusPoint Capital Management first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 6 quarters since.
ExodusPoint Capital Management's Dianthus Therapeutics position peaked at $10.2M in Q4 2025.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.